SCHEMBL23409584

SCHEMBL23409584

CNC(=O)COc1cc(Cl)c(Cc2ccc(O)c(C(C)C)c2)c(Cl)c1F

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 18/20 0.56
▸ THRB P10828 18/20 0.56
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901415 1.00 THRA (0.56) THRATHRBBCHEACHE
SCHEMBL23409512 0.93 THRA (0.57) THRATHRBBCHEACHE
SCHEMBL29901375 0.93 THRA (0.57) THRATHRBBCHEACHE
SCHEMBL29901402 0.92 THRB (0.51) THRATHRBBCHEACHE
SCHEMBL23409507 0.92 THRB (0.51) THRATHRBBCHEACHE
SCHEMBL23409426 0.91 THRB (0.55) THRATHRBBCHEACHE
SCHEMBL29901378 0.91 THRB (0.55) THRATHRBBCHEACHE
SCHEMBL23409595 0.91 THRB (0.53) THRATHRBBCHEACHE
SCHEMBL29901452 0.91 THRB (0.53) THRATHRBBCHEACHE
SCHEMBL23409415 0.90 THRA (0.49) THRATHRBBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 — — US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 — — US disclosed
WO-2022236133-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
CN-115279359-A Novel thyromimetic agents 速通医疗公司 2022-11-01 — — CN disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 — — WO disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 THRA 8/4885THRB 9/4885BCHE 534/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 THRA 6/4885THRB 9/4885BCHE 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback